Clinical Trial Update: Temodal (Temozolomide) Post Marketing Surveillance Protocol (Study P05557AM2)

View source ↗

Summary

This is a post-marketing surveillance protocol update for Temozolomide (Temodal) in patients with glioblastoma, glioma, and astrocytoma; the study is completed …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Astrocytoma
• Glioblastoma
• Glioma

Drugs mentioned

• Temodal (temozolomide)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Glioblastoma, Glioma | Status: COMPLETED | Results posted: 2013-01-08